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Background
Acid suppressive drugs, one of the most
frequently prescribed drug classes, continue to
grow in sales.1 Yet their use is not without risk.2
The normal pH of the stomach is a host
defense and barrier to ingested pathogens.3
Bacterial overgrowth and colonization with upper
gastrointestinal tract bacteria have been identified
in studies with acid-inhibitory therapy.3,4 Acidsuppressing drugs are associated with bacterial
overgrowth in the stomach and influenza viruses
in the gastric mucosa.3,5 Studies have also shown
that bacterial overgrowth depends on the intensity
of inhibition of gastric acid secretion and
corresponding increase in pH. Both H2 receptor
antagonists (H2RAs) and proton pump inhibitors
(PPIs) effectively raise gastric pH. Proton pump
inhibitors have greater inhibition of gastric acid
receptor
secretion
compared
with
H2
antagonists.4,6
Colonized oral secretions can be aspirated into
the lungs and establish pneumonia.7
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Methods
Complete medical records for approximately
half a million patients were accessed from the
Integrated Primary Care Information project, a
Dutch general practice research database. The
seven-year study included all patients with at least
a one-year recorded history. All participants were
followed once they had a one-year history until
the study ended, or until they had pneumonia,
died, or moved out of the practice area. All those
with a pre-study pneumonia diagnosis were
excluded.
All patients exposed to acidsuppressive therapy were compared to those who

did not receive this therapy in the study period
relative to their incidence of community-acquired
pneumonia. Incidence rates were calculated for
exposed and unexposed participants. To prevent
confounding by antagonist indication, a nested
case-control analysis of patients with pneumonia
and using acid-suppressive drugs prior to or at the
time of contracting pneumonia was conducted.

Results
A total of 364,683 suppressive therapy
exposed and unexposed patients were identified.
Person-time of exposure was calculated on the
basis of person-years. Overall, 5.3% of these
individuals were exposed to suppressive drugs.
This represented 7562 person-years. During the
study period, 185 cases of radiographic or sputum
culture confirmed-pneumonia occurred.
The
incidence rate of pneumonia in acid-suppressive
users was 2.45 and for non-suppressive
participants the rate was 0.6 per 100 person-years.
The adjusted relative risk for pneumonia for those
currently using PPIs compared with those who
stopped using PPIs was 1.89 (95% confidence
interval, 1.36 to 2.62). H2RA current users had a
1.63 adjusted relative risk for pneumonia (95%
confidence interval, 1.07 to 2.48) compared with
those who stopped their use.
A significant dose response was observed in
PPI users taking more than one dose per day.
They had a 2.3-fold increased risk of pneumonia
compared with past acid-suppressive drug users.
This dose response was not observed with H2RAs.

Author Conclusions
Both H2RA and PPI acid-suppressive drugs are
associated with an increase in communityacquired pneumonia risk.
This association
probably results from their effective suppression
of gastric pH which facilitates opportunistic
infection by intestinal bacterial and viral
organisms.
More. . .
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Commentary
The availability of acid-suppressive therapy is
a major factor in the effective treatment of
gastrointestinal ulcerative disease. The rational
use of these agents is associated with both
efficacy and safety. They represent a major
milestone for improvement of the quality of life in
patients suffering from these common disorders.
As demonstrated in this study, despite their
safety and efficacy, acid-suppressive agents can
present risk for certain patients.
In another study of 700 patients by Laheij RJ,
et al, those using acid-suppressive drugs were
2.34 times more likely (95% confidence interval,
1.4 to 4.1) than non-suppressive users to have
clinical signs of infection. They also visited a
physician 3.72 times more often (95% confidence
interval, 2.1 to 6.8) for an infection and received
an antibiotic 4.19 times more often (95%
confidence interval, 2.2 to 8.1) compared with
non-suppressive users.8
In a recent investigation, both cohort and casecontrolled studies were undertaken to assess acidsuppressive therapy as a risk factor for C. difficile
infection. C. difficile diarrhea developed in 6.8%
of the 1,187 cohort patients. Of the patients who
received antibiotics and a PPI, 9.3% developed C.
difficile diarrhea, whereas those who received
antibiotics but no PPI experienced a 4.4%
incidence (RR 2.1, 95% CI 1.4 to 3.4). The
relative risk of C. difficile was higher in patients
receiving PPIs compared with H2RA recipients
(OR 2.1, 95% CI 1.2 to 3.5 vs. OR 1.1, 95% CI
0.4 to 3.4).9
In the case-control study, 94 patients
developed C. difficile diarrhea. The case and
control subjects were similar in age, number and
type of antibiotic, and comorbidity factors. Of the
cases, 64% were receiving PPIs as compared with
36% of the controls (unadjusted OR 3.1, 95% CI
1.7 to 5.6).9
These authors concluded that patients
receiving PPIs were at greater risk for C. difficile
diarrhea.9
Given these concerns associated with acidsuppressive therapy, at-risk patients should be
identified. Community-acquired pneumonia is a
danger for those who are generally at risk for
infection.10 At risk groups include those with
asthma, chronic obstructive pulmonary disease,
children, the elderly, and those who are
immunocompromised.11 In these at risk groups,

patients needing acid-suppressive therapy may
benefit from sucralfate (Carafate) which does not
appear to affect gastric acid concentration.12
Evidence presented in this study suggests that
patients should be treated with acid-suppressing
drugs only when necessary and at the lowest
effective dose [Evidence level B, epidemiologic
study, clinical cohort study].2

Users of this document are cautioned to use their own
professional judgment and consult any other necessary
or appropriate sources prior to making clinical
judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.

Levels of Evidence
In accordance with the trend towards Evidence-Based
Medicine, we are citing the LEVEL OF EVIDENCE
for the statements we publish.
Level
A

B

C
D

Definition
High-quality randomized controlled trial (RCT)
High-quality meta-analysis (quantitative
systematic review)
Nonrandomized clinical trial
Nonquantitative systematic review
Lower quality RCT
Clinical cohort study
Case-control study
Historical control
Epidemiologic study
Consensus
Expert opinion
Anecdotal evidence
In vitro or animal study

Adapted from Siwek J, et al. How to write an evidence-based
clinical review article. Am Fam Physician 2002;65:251-8.
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